TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06632405
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT06632405
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT06632405
Drug: Levocetirizine Hydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg daily, start 3 days before the 1st administration
Study: NCT06785402
Drug: Ceftriaxone treatment
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 infusions spaced out approximately every 5 days
Study: NCT05769777
Drug: Amlitelimab
Normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
Study: NCT06752850
Drug: Efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU/kg once weekly, Intravenous injection
Study: NCT05846880
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
Study: NCT05846880
Drug: Maintenance Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
Study: NCT05846880
Drug: No maintenance Vitamin D
Normalized name: Vitamin D NOS
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
Study: NCT06507436
Drug: Herombopag tablets
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herombopag tablets; dose 1 or dose 2, for 5 days
Study: NCT05141708
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
Study: NCT04750226
Drug: ABBV-951
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for continuous subcutaneous infusion (CSCI).
Study: NCT06010758
Drug: Colgate Cavity Protection Toothpaste
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
Study: NCT04611958
Drug: ERCP with Bupivacaine infusion
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom.
Study: NCT05686746
Drug: Baricitinib 4 MG
Normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg oral daily
Study: NCT05686746
Drug: Baricitinib 2 MG
Normalized name: baricitinib 2 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg oral daily
Study: NCT05686746
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg oral daily
Study: NCT06178848
Drug: propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Study: NCT06178848
Drug: remimazolam group
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Study: NCT05806515
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06090981
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
Study: NCT05803863
Drug: Myatro XL
Normalized name: XL-888
DrugBank: XL-888 (DB12981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: myopia control with 0.05% atropine drops
Study: NCT05547399
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally as a tablet or capsule
Study: NCT04973683
Drug: AL101
Normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06598787
Drug: BL-B01D1 for Injection
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06658964
Drug: Cohort 1: JMKX003142 and itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD
Study: NCT06660940
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD
Study: NCT06658652
Drug: Enlicitide decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06668571
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive 1:1 single IV racemic ketamine (dosed @0.5 mg/kg actual body weight) (n=15) 40-min infusion in an MRI scanner, followed by an optional open-label ketamine infusion (available to everyone) 1-7 days after the initial treatment
Study: NCT06660693
Drug: Upadacitinib Oral Product
Normalized name: upadacitinib Oral Product
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib oral 45mg once daily.
Study: NCT04870671
Drug: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
Study: NCT04707768
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral tablets
Study: NCT06660017
Drug: Ketamine Topical
Normalized name: ketamine topical
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
Study: NCT06659770
Drug: Zevorcabtagene Autoleucel
Normalized name: Zevorcabtagene autoleucel
DrugBank: Zevorcabtagene autoleucel (DB17266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
Study: NCT06600282
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmacokinetic study under fasting conditions
Study: NCT04926831
Drug: capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg and 200 mg tablets for oral administration
Study: NCT06673667
Drug: KT-621
Normalized name: adalimumab
DrugBank: T-62 (DB12919)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral drug
Study: NCT05034627
Drug: Calaspargase Pegol-mknl
Normalized name: calaspargase pegol-mknl
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05034627
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT06620302
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06149481
Drug: Retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg infused via IV over 30 minutes every 28 days
Study: NCT06149481
Drug: N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ug/kg administered via subcutaneous injection to the abdomen every 28 days
Study: NCT06149481
Drug: SX-682
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg administered orally twice per day on days 6-26 of every cycle
Study: NCT05319730
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
Study: NCT05319730
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
Study: NCT05319730
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg oral administration every day.
Study: NCT05319730
Drug: Antihistamine
Normalized name: Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per product label.
Study: NCT05319730
Drug: H2 Receptor Antagonist
Normalized name: Histamine H2 receptor antagonist
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered per product label.
Study: NCT05319730
Drug: Dexamethasone (or equivalent)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered per product label.
Study: NCT05319730
Drug: Steroid Mouthwash (dexamethasone or equivalent)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered per product label.
Study: NCT06682728
Drug: Sacituzumab Govitecan (SG)
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT06682728
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06690242
Drug: Etelcalcetide Hydrochloride
Normalized name: Etelcalcetide hydrochloride
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: the already-marketed therapeutic agents
Study: NCT06716619
Drug: Serplulimab Injection
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Srulizumab injection was given intravenous infusion both before and after the TAL-T cells infusion.
Study: NCT06721299
Drug: Clenbuterol
Normalized name: clenbuterol
DrugBank: Clenbuterol (DB01407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Agonist
Study: NCT06723015
Drug: 18F-AV-1451
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.~Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..
Study: NCT05644977
Drug: Emraclidine
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06721689
Drug: PEEL-224
Normalized name: orange peel
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor
Study: NCT06721689
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.
Study: NCT06721689
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.
Study: NCT00049959
Drug: verteporfin PDT
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04234048
Drug: Fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort
Study: NCT06795581
Drug: 18F-PF-06445974
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected IV followed by PET scanning
Study: NCT06143891
Drug: Belumosudil
Normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT06143891
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Study: NCT06714123
Drug: Senicapoc
Normalized name: Senicapoc
DrugBank: Senicapoc (DB06280)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administering 30 mg senicapoc a day, in addition to standard of care.
Study: NCT06753071
Drug: Pyridostigmine oral tablet
Normalized name: pyridostigmine Oral Tablet
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
Study: NCT06782139
Drug: Enavogliflozin
Normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
Study: NCT06660173
Drug: Maridebart Cafraglutide
Normalized name: Maridebart Cafraglutide
DrugBank: Maridebart Cafraglutide (DB19339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection.
Study: NCT05417594
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive temozolomide orally.
Study: NCT05417594
Drug: Datopotamab Deruxtecan (Dato-DXd)
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Dato-DXd intravenously.
Study: NCT05417594
Drug: Trastuzumab Deruxtecan (T-DXd)
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive T-DXd intravenously.
Study: NCT06766305
Drug: QL1706 combined with SOX
Normalized name: miconazole
DrugBank: QL1706 (DB17562)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: QL1706 + SOX (3 cycles) before surgery → radical surgery (D2) → QL1706 + SOX (5 cycles) after surgery → QL1706 monotherapy maintenance （up to 1 year before and after surgery); Phase 1 (initial dose cohort) ： QL1706 5mg/kg ；Phase 1 (dose escalation cohort)：QL1706 7.5mg/kg ；Phase 2：QL1706 RP2D
Study: NCT06766266
Drug: Irinotecan liposome II combination therapy regimen
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the neoadjuvant therapy phase before TURBT surgery.
Study: NCT06766266
Drug: Irinotecan liposome II combination therapy regimen
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the B arm, the combined therapy with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2 ) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the induction phase after TURBT surgery.
Study: NCT06572982
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg Film coated tablets
Study: NCT06751602
Drug: Belumosudil 200 mg QD
Normalized name: belumosudil 200 MG
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belumosudil 200 mcg oral daily
Study: NCT06740214
Drug: 0.5% standard bupivacaine only
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml 0.5% standard bupivacaine only
Study: NCT06740214
Drug: 1.33% liposomal bupivacaine with 0.5% standard bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10ml 1.33% liposomal bupivacaine (133mg) plus 10ml 0.5% standard bupivacaine
Study: NCT06740214
Drug: 1.33% liposomal bupivacaine only
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml 1.33% liposomal bupivacaine (266mg)
Study: NCT05952557
Drug: Camizestrant
Normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camizestrant. Experimental. Administered orally
Study: NCT05952557
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen. Comparator. Administered orally
Study: NCT05952557
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole. Comparator. Administered orally
Study: NCT05952557
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole. Comparator. Administered orally
Study: NCT05952557
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane. Comparator. Administered orally
Study: NCT05952557
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib adjuvant treatment Administered orally
Study: NCT06222827
Drug: Satralizumab Prefilled Syringe
Normalized name: satralizumab Prefilled Syringe
DrugBank: Satralizumab (DB15762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Satralizumab is supplied as prefilled syringe with 1 millimeter of solution for subcutaneous injection corresponding to 120mg of satralizumab. During the first period (double blind period), satralizumab will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
Study: NCT06008756
Drug: Enlicitide Decanoate
Normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enlicitide Decanoate 20 mg tablet taken by mouth.
Study: NCT06564623
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV every 4 weeks in both the Prime and Boost Phase.
Study: NCT06564623
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment on C1D1. Tremelimumab (300 mg) will be administered IV as a single dose on Day 1 of Cycle 1.
Study: NCT05649748
Drug: Treprostinil Palmitil
Normalized name: Treprostinil palmitil
DrugBank: Treprostinil palmitil (DB18792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
Study: NCT05581004
Drug: RO7502175
Normalized name: RO7502175
DrugBank: RO7502175 (DB17502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7502175 will be administered as per the schedules specified in the respective arms.
Study: NCT05581004
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.